At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 222 enrolled
Drug / intervention
exenatide once weekly +1 moredrug
Likely dose
exenatide once weekly 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulphonylurea
In Brief
A Phase 3 clinical trial evaluating exenatide once weekly and insulin detemir for Type 2 Diabetes Mellitus. Completed, enrolled 222 participants across 34 sites in 2 countries.
Detailed Summary
The purpose of this study is to compare the effects of exenatide once weekly (QW) and insulin detemir with respect to glycemic control, body weight, lipids, safety, tolerability, and patient reported outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesIreland, United Kingdom
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedOct 2009
Primary CompletionJul 2011
Study CompletionDec 2011
TodayJul 2026
First PostedOct 28, 2009
Enrollment StartOct 1, 2009
Primary CompletionJul 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.7 years ago
Interventions
exenatide once weeklydrug
subcutaneous injection, 2mg, once a week
insulin detemirdrug
subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day